Nintedanib Eurogenerics

Nintedanib, the active ingredient in Nintedanib Eurogenerics, is a tyrosine kinase inhibitor presented as a generic oral tablet for oral use. It is used to treat idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease and certain cases of non‑small cell lung cancer in adult patients.

GNH USA supplies Nintedanib Eurogenerics as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nintedanib is an antifibrotic and anti‑angiogenic agent indicated for several progressive lung disorders. - Idiopathic pulmonary fibrosis: slows decline in lung function and reduces disease progression. - Systemic sclerosis‑associated interstitial lung disease: improves forced vital capacity and delays respiratory deterioration. - Non‑small cell lung cancer (in combination therapy): inhibits tumor cell proliferation and angiogenesis, contributing to disease control.

Nintedanib may cause a range of adverse reactions, most of which are manageable with monitoring and supportive care.

Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea: sensation of unease or urge to vomit. - Vomiting: expulsion of stomach contents. - Abdominal pain: discomfort or cramping in the stomach area. - Decreased appetite: reduced desire to eat. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Elevated liver enzymes: potential indication of hepatic injury. - Bleeding events: including gastrointestinal or pulmonary hemorrhage. - Cardiovascular events: such as hypertension or myocardial infarction. - Severe infections: opportunistic or bacterial infections requiring medical attention. - Gastrointestinal perforation: rare but serious tearing of the GI tract. - Interstitial lung disease worsening: rare exacerbation of underlying lung disease.

Before initiating therapy, clinicians should assess patient suitability and monitor for specific risks. - Liver function monitoring: check ALT/AST levels regularly. - Bleeding risk assessment: evaluate concomitant anticoagulant or antiplatelet use. - Cardiovascular evaluation: screen for hypertension or cardiac disease. - Gastrointestinal symptom management: advise patients to report persistent diarrhea or abdominal pain. - Avoid use in severe hepatic impairment: contraindicated when liver function is markedly compromised. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Nintedanib interacts with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk. - Antiplatelet agents (e.g., aspirin, clopidogrel): additive hemorrhagic potential. - P‑gp inhibitors (e.g., verapamil, quinidine): can raise plasma concentrations. - High‑dose aspirin (>325 mg/day): may exacerbate gastrointestinal toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Diuretics: monitor electrolytes and renal function. - NSAIDs: increase risk of gastrointestinal bleeding. - Proton‑pump inhibitors: may affect absorption, watch for reduced efficacy. - Herbal supplements (e.g., St John’s wort): potential CYP3A4 induction.